BC
TEVA icon

Broadfin Capital’s Teva Pharmaceuticals TEVA Stock Holding History

Broadfin Capital’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-647,500
Closed -$23.5M – 63
2016
Q4 		$23.5M Buy
647,500
+347,500
+116% +$13.9M 2.61% 12
2016
Q3 		$13.8M Buy
+300,000
New +$15.7M 1.24% 24
2014
Q2 		– Sell
-291,636
Closed -$14.9M – 79
2014
Q1 		$15.4M Sell
291,636
-550,100
-65% -$25.4M 1.49% 23
2013
Q4 		$33.7M Buy
841,736
+200,000
+31% +$7.88M 4.45% 4
2013
Q3 		$24.2M Sell
641,736
-221,500
-26% -$8.64M 4.3% 7
2013
Q2 		$33.8M Buy
+863,236
New +$33.6M 6.62% 2

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $33B AUM 40.62% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Broadfin Capital's TEVA Position: Q1 2017 in Review

Broadfin Capital sold out of Teva Pharmaceuticals (TEVA) in Q1 2017, closing a stake of 647,500 shares — an estimated $23.5M sold.

Broadfin Capital first reported a position in TEVA in Q2 2013 and held it in 6 quarters. The position peaked at $33.8M in Q2 2013. 688 funds tracked by Wall St. Rank hold TEVA as of Q1 2017.

  • Broadfin Capital reported no remaining Teva Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Broadfin Capital sold 647,500 Teva Pharmaceuticals shares in Q1 2017, an estimated $23.5M.
  • Broadfin Capital first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 6 quarters.
  • Broadfin Capital's Teva Pharmaceuticals position peaked at $33.8M in Q2 2013.
  • 688 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2017.

Based on Broadfin Capital's 13F filing for Q1 2017, filed 15 May 2017.